Predicting Treatment Response Based on RNA Expression in Large Datasets.

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)

PD-L1 expression levels derived from >16,000 samples guided the selection of tumor types likely to benefit from pembrolizuamb monotherapy in clinical trials. Although not fail-proof, FDA approvals for most of the prioritized indications speak to the power of RNA expression profiling and the value of large genomic datasets.See related article by Ayers et al., p. 1564.

Keyphrases

clinical trial
poor prognosis
rna seq
open label
nucleic acid
genome wide
copy number
randomized controlled trial
phase ii
binding protein
dna methylation
transcription factor
phase iii
study protocol